ArticleFrontiers in neuroscience2026
A neuron-distributed DEK integrates ac4C modification and neuroinflammation in pathogenesis of Parkinson disease: evidence from Mendelian randomization, multi-omics and
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epi-transcriptomic modifications, particularly N4-acetylcytidine (ac4C), and chronic neuroinflammation have emerged as pivotal players in the pathogenesis of Parkinson's disease (PD). However, the specific molecular co-expression patterns linking ac4C RNA modification to neuronal inflammatory responses remains largely uncharted. Objective: This study aimed to decode the ac4C-neuroinflammation (AN)-associated molecular patterns in PD and to identify a neuron-specific central pathogenic and therapeutic factor. Methods: We integrated multi-omics analyses by using peripheral blood bulk transcriptomes (GSE18838, GSE49126, GSE22491, GSE6613, and GSE57475) and GWAS data from PD patients for identification of AN-related risk genes. Next, consensus clustering and 3 machine learning algorithms (LASSO, RF, and SVM-RFE) were applied for patient stratification, hub gene identification, and diagnostic modeling. Single-cell transcriptomic profiling of PD patients (GSE140231) was leveraged to map the cellular distribution and mechanistic roles of the hub gene within the substantia nigra (SN). An AI-driven active learning framework and the CTD database were utilized to screen therapeutic candidates targeting the hub gene, with binding affinities validated via molecular docking. Results: We pinpointed 7 AN-associated risk DEGs for PD patients, including HSP90AA1, DEK, LEF1, IRF2, BCL2L1, CFL1, and BCR, which effectively stratified PD patients into 2 distinct immune-molecular subgroups. DEK can be considered as neuron-distributed and up-regulated AN-associated central pathogenic factor for PD patients. The DrugReflector active learning framework identified BRD-K57589644 as a computationally prioritized compound warranting further investigation. Conclusion: This study establishes a novel AN-associated molecular patterns in PD, identifying DEK as a computationally identified neuron-specific factor associated with ac4C modification and neuroinflammatory cascades for PD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.